Literature DB >> 14557637

Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes.

R S Midgley1, A I Bell, D J McGeoch, A B Rickinson.   

Abstract

Epstein-Barr virus (EBV) strains from the highly HLA-A11-positive Chinese population are predominantly type 1 and show a variety of sequence changes (relative to the contemporary Caucasian prototype strain B95.8) in the nuclear antigen EBNA3B sequences encoding two immunodominant HLA-A11 epitopes, here called IVT and AVF. This has been interpreted by some as evidence of immune selection and by others as random genetic drift. To study epitope variation in a broader genomic context, we sequenced the whole of EBNA3B and parts of the EBNA2, 3A, and 3C genes from each of 31 Chinese EBV isolates. At each locus, type 1 viruses showed <2% nucleotide divergence from the B95.8 prototype while type 2 sequences remained even closer to the contemporary African prototype Ag876. However, type 1 isolates could clearly be divided into families based on linked patterns of sequence divergence from B95.8 across all four EBNA loci. Different patterns of IVT and AVF variation were associated with the different type 1 families, and there was additional epitope diversity within families. When the EBNA3 gene sequences of type 1 Chinese strains were subject to computer-based analysis, particular codons within the A11-epitope-coding region were among the few identified as being under positive or diversifying selection pressure. From these results, and the observation that mutant epitopes are consistently nonimmunogenic in vivo, we conclude that the immune selection hypothesis remains viable and worthy of further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557637      PMCID: PMC229270          DOI: 10.1128/jvi.77.21.11517-11530.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Codon-substitution models for heterogeneous selection pressure at amino acid sites.

Authors:  Z Yang; R Nielsen; N Goldman; A M Pedersen
Journal:  Genetics       Date:  2000-05       Impact factor: 4.562

Review 2.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift.

Authors:  R Khanna; R W Slade; L Poulsen; D J Moss; S R Burrows; J Nicholls; J M Burrows
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

5.  Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene.

Authors:  R Nielsen; Z Yang
Journal:  Genetics       Date:  1998-03       Impact factor: 4.562

6.  A codon-based model of nucleotide substitution for protein-coding DNA sequences.

Authors:  N Goldman; Z Yang
Journal:  Mol Biol Evol       Date:  1994-09       Impact factor: 16.240

7.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Authors:  R S Midgley; A I Bell; Q Y Yao; D Croom-Carter; A D Hislop; B M Whitney; A T C Chan; P J Johnson; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  EBV strain variation: geographical distribution and relation to disease state.

Authors:  M Abdel-Hamid; J J Chen; N Constantine; M Massoud; N Raab-Traub
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

10.  Statistical methods for detecting molecular adaptation.

Authors: 
Journal:  Trends Ecol Evol       Date:  2000-12-01       Impact factor: 17.712

View more
  21 in total

1.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

Authors:  Robert E White; Patrick C Rämer; Kikkeri N Naresh; Sonja Meixlsperger; Laurie Pinaud; Cliona Rooney; Barbara Savoldo; Rita Coutinho; Csaba Bödör; John Gribben; Hazem A Ibrahim; Mark Bower; Jamie P Nourse; Maher K Gandhi; Jaap Middeldorp; Fathima Z Cader; Paul Murray; Christian Münz; Martin J Allday
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.

Authors:  C W Tsang; X Lin; N H Gudgeon; G S Taylor; H Jia; E P Hui; A T C Chan; C K Lin; A B Rickinson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Genomic variation of the fibropapilloma-associated marine turtle herpesvirus across seven geographic areas and three host species.

Authors:  Rebecca J Greenblatt; Sandra L Quackenbush; Rufina N Casey; Joel Rovnak; George H Balazs; Thierry M Work; James W Casey; Claudia A Sutton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

5.  HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Authors:  R S Midgley; A I Bell; Q Y Yao; D Croom-Carter; A D Hislop; B M Whitney; A T C Chan; P J Johnson; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.

Authors:  Yong Zheng; Greg Parsonage; Xiaodong Zhuang; Lee R Machado; Christine H James; Asmaa Salman; Peter F Searle; Edwin P Hui; Anthony T C Chan; Steven P Lee
Journal:  Cancer Immunol Res       Date:  2015-02-24       Impact factor: 11.151

7.  Autophagy and ATP-induced anti-apoptosis in antigen presenting cells (APC) follows the cytokine storm in patients after major trauma.

Authors:  E Marion Schneider; Sarah Flacke; Fengguang Liu; Myriam R Lorenz; Patricia Schilling; Max E Nass; Karl J Foehr; Markus Huber-Lang; Manfred E Weiss
Journal:  J Cell Commun Signal       Date:  2011-01-13       Impact factor: 5.782

8.  Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy.

Authors:  Hin Kwok; Amy H Y Tong; Chi Ho Lin; Si Lok; Paul J Farrell; Dora L W Kwong; Alan K S Chiang
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

9.  T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.

Authors:  Laura K Mackay; Heather M Long; Jill M Brooks; Graham S Taylor; Carol S Leung; Adrienne Chen; Fred Wang; Alan B Rickinson
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

10.  A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Authors:  Graham S Taylor; Hui Jia; Kevin Harrington; Lip Wai Lee; James Turner; Kristin Ladell; David A Price; Manjit Tanday; Jen Matthews; Claudia Roberts; Ceri Edwards; Lesley McGuigan; Andrew Hartley; Steve Wilson; Edwin P Hui; Anthony T C Chan; Alan B Rickinson; Neil M Steven
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.